<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The heat shock protein 70 (HSP70) is one of the molecular chaperone family involved in the protection of cells upon exposure to various types of stresses </plain></SENT>
<SENT sid="1" pm="."><plain>Plasma circulating HSP70 (cHSP70) is believed to play a role in the anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> immune responses and its levels may reflect the levels of severity or the disease condition </plain></SENT>
<SENT sid="2" pm="."><plain>Using electrochemiluminescence protein detection immunoassay, we measured the cHSP70 levels in the plasma of patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) (n=96), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) (n=28), and <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) (n=40) and compared with those in <z:mpath ids='MPATH_458'>normal</z:mpath> individuals (n=99) </plain></SENT>
<SENT sid="3" pm="."><plain>cHSP70 levels were significantly higher in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (median: 10.71 ng/mL, range: 1.93-79.0 ng/mL) and ALL (median: 27.59 ng/mL, range: 5.09-129.6 ng/mL) as compared to those in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (median: 4.54 ng/mL, range: 1.35-58.3 ng/mL) or healthy controls (median: 4.13 ng/mL, range: 1.75-13.6 ng/mL) </plain></SENT>
<SENT sid="4" pm="."><plain>Levels of cHSP70 showed significant positive correlation with <z:chebi fb="4" ids="24996">lactate</z:chebi> dehydrogenase (LDH) and white blood cells (WBC) in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and ALL patients, which may reflect overall <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> load </plain></SENT>
<SENT sid="5" pm="."><plain>Furthermore, patients with higher levels of cHSP70 had significantly shorter survival in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (P=0.04) and ALL (P=0.05), suggesting that in these two <z:hpo ids='HP_0011009'>acute</z:hpo> diseases, cHSP70 is an indicator for poor prognosis </plain></SENT>
<SENT sid="6" pm="."><plain>Our data support the potential of using free cHSP70 as a biomarker in <z:hpo ids='HP_0001909'>leukemias</z:hpo> and potentially other types of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
</text></document>